



Bixlenvo™ (bictegravir/lenacapavir)

Use in Pediatric and Adolescent Individuals

This document is in response to your request for information regarding the use of Bixlenvo™ (bictegravir/lenacapavir [BIC/LEN]) in pediatric and adolescent individuals.

Some data may be outside of the US FDA-approved prescribing information. In providing this data, Gilead Sciences, Inc. is not making any representation as to its clinical relevance or to the use of any Gilead product(s). For information about the approved conditions of use of any Gilead drug product, please consult the FDA-approved prescribing information.

The full indication, important safety information, and boxed warnings are available at: www.gilead.com/-/media/files/pdfs/medicines/hiv/BIXLENVO/BIXLENVO_pi.

Product Labeling¹

The safety and effectiveness of BIC/LEN have not been established in patients less than 18 years of age.

Clinical Data

Currently there is no data to address this inquiry. The ARTISTRY-1 and ARTISTRY-2 studies enrolled participants who were aged 18 years or older.^{2,3}

GS-US-621-6463 ([NCT06532656](https://clinicaltrials.gov/ct2/show/study/NCT06532656)) is an ongoing phase 2/3 study evaluating the safety, tolerability and PK of BIC/LEN in virologically suppressed children and adolescents with HIV-1 on a stable and complex ARV regimen. The study will also assess the safe loading dose of LEN in this population.⁴

Literature search

A literature search was conducted in Ovid MEDLINE and Embase databases for studies published between 1946 and August 10th 2026 using search terms that included bictegravir, lenacapavir, child, pediatric, adolescent and other related search terms. No relevant citations were identified.

References

1. Enclosed, Gilead Sciences Inc. BIXLENVO™ (bictegravir and lenacapavir) tablets, for oral use. U.S. Prescribing Information. Foster City, CA.
2. ClinicalTrials.gov. Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1). Available at: <https://classic.clinicaltrials.gov/ct2/show/NCT05502341>

Gilead Sciences, Inc. is providing this document to you, a US Healthcare Professional, in response to your unsolicited request for medical information.

3. ClinicalTrials.gov. Study to Compare Bictegravir/ Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy (ARTISTRY-2). Available at: <https://clinicaltrials.gov/study/NCT06333808#participation-criteria>.
4. ClinicalTrials.gov. Study of Bictegravir/ Lenacapavir in Children and Adolescents With HIV-1. Available at: <https://clinicaltrials.gov/study/NCT06532656>.

Abbreviations

ARV=antiretroviral

BIC=bictegravir

LEN=lenacapavir
PK=pharmacokinetics

Product Label

For the full indication, important safety information, and boxed warning(s), please refer to the Bixlenvo US Prescribing Information available at:

www.gilead.com/-/media/files/pdfs/medicines/hiv/BIXLENVO/BIXLENVO_pi.

Follow-Up

For any additional questions, please contact Gilead Medical Information at:

☎ 1-866-MEDI-GSI (1-866-633-4474) or 🌐 www.askgileadmedical.com

Adverse Event Reporting

Please report all adverse events to:

Gilead Global Patient Safety ☎ 1-800-445-3235, option 3 or

🌐 www.gilead.com/utility/contact/report-an-adverse-event

FDA MedWatch Program by ☎ 1-800-FDA-1088 or ✉ MedWatch, FDA, 5600 Fishers Ln, Rockville, MD 20852 or 🌐 www.accessdata.fda.gov/scripts/medwatch

Data Privacy

The Medical Information service at Gilead Sciences may collect, store, and use your personal information to provide a response to your medical request. We may share your information with other Gilead Sciences colleagues to ensure that your request is addressed appropriately. If you report an adverse event or concern about the quality of a Gilead or Kite product, we will need to use the information you have given us in order to meet our regulatory requirements in relation to the safety of our medicines.

It may be necessary for us to share your information with Gilead's affiliates, business partners, service providers, and regulatory authorities located in countries besides your own. Gilead Sciences has implemented measures to protect the personal information you provide. Please see the Gilead Privacy Statement (www.gilead.com/privacy-statements) for more information about how Gilead handles your personal information and your rights. If you have any further questions about the use of your personal information, please contact gilead.privacy@gilead.com.

BIXLENVO, GILEAD, and the GILEAD logo are trademarks of Gilead Sciences, Inc., or its related companies.

© 2026 Gilead Sciences, Inc.